Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

TWi Biotechnology completes enrolment in Phase II AC-203 trial

EpidermolysisBullosa (EB) is characterised by skin fragilityand repeated blister formation. Credit: Jordan Garn.



  • TWi Biotechnology

Go Top